Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

Stock Information for Adaptimmune Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adaptimmune Therapeutics plc

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCCI, KLR, PRTK
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, NEWR, PRTK
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CEQP, CELL, DINO, PRTK
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.